从2000年到2020年,在接受美特福林治疗的患者中进行维生素B12水平测试的趋势
Debarati Bhanja1, Areeba Zain2, Camille Moeckel1
1College of Medicine, Pennsylvania State University, Hershey, PA.
PRiMER (Leawood, Kan.)
|July 1, 2024
概括
甲福明使用者的维生素B12测试显著下降,这可能会阻碍早期发现缺乏症. 这一趋势影响了2型糖尿病和相关并发症的管理.
科学领域:
- 内分泌学 在内分泌学.
- 临床药理学 临床药理学
- 公共卫生 公共卫生
背景情况:
- 甲福明是2型糖尿病 (T2DM) 的第一线治疗方法.
- 梅特福林的使用与维生素B12的吸收不良和缺乏有关.
- 在T2DM患者中诊断维生素B12缺乏症可能具有挑战性,因为症状与多神经病变重叠.
研究的目的:
- 为了检查2000年至2020年之间服用甲福明的患者中维生素B12水平测试的趋势.
- 评估改变实践指南对诊断测试利用的潜在影响.
主要方法:
- 使用TrinetX真实世界的临床数据库进行回顾性趋势分析.
- 鉴定2000年至2020年期间接受甲福明治疗的患者.
- 随着时间的推移,维生素B12检测率的表格化和统计分析.
主要成果:
- 分析了超过420万接受甲福明治疗的患者,25.1%接受了维生素B12测试.
- 维生素B12测试的使用率从39.6% (2000-2002) 显著下降到20.1% (2018-2020).
- 在研究期间,检测率下降了19.5% (P=.001).
结论:
- 在接受甲福林治疗的患者中,维生素B12水平测试显著下降.
- 这种趋势可能会阻碍及时诊断维生素B12缺乏症.
- 需要进一步的研究来阐明这种下降的原因和临床影响.
相关概念视频
01:20Determination of Michaelis Constant and Maximum Elimination Rate
89
The Michaelis constant (KM) and the theoretical maximum process rate (Vmax) are vital parameters in the Michaelis-Menten equation, central to many biochemical reactions. They provide essential insights into enzyme kinetics and drug metabolism.
These parameters can be estimated by analyzing plasma concentration data post-drug administration. A notable example of this application is phenytoin, a drug with capacity-limited kinetics. It's recommended that phenytoin should be administered at two...
These parameters can be estimated by analyzing plasma concentration data post-drug administration. A notable example of this application is phenytoin, a drug with capacity-limited kinetics. It's recommended that phenytoin should be administered at two...
89
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188